Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines

INTRODUCTION: Off-label use of medicines is generally discouraged. However, several off-patent, low-cost cancer medicines remain off-label for indications in which they are commonly used in daily practice, supported by high-level evidence based on results of phase III clinical trials. This discrepan...

Descripción completa

Detalles Bibliográficos
Autores principales: Zarkavelis, G., Amylidi, A.L., Verbaanderd, C., Cherny, N.I., Metaxas, Y., de Vries, E.G.E., Zygoura, P., Amaral, T., Jordan, K., Strijbos, M., Dafni, U., Latino, N., Galotti, M., Lordick, F., Giuliani, R., Pignatti, F., Pentheroudakis, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024100/
https://www.ncbi.nlm.nih.gov/pubmed/36870739
http://dx.doi.org/10.1016/j.esmoop.2022.100604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024100/
https://www.ncbi.nlm.nih.gov/pubmed/36870739
http://dx.doi.org/10.1016/j.esmoop.2022.100604

Ejemplares similares